PYNNACLEII期临床试验协议:rezatapopt (PC14586) 单疗法用于具有TP53 Y220C突变的晚期或转移性实体瘤
Alison M Schram1, Marc Fellous2, Kim LeDuke2
1Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Future oncology (London, England)
|September 11, 2025
概括
这项研究调查了新型治疗策略的疗效. 这些发现突出了患者护理和治疗结果的潜在进步.
科学领域:
- 这项研究属于临床药理学和治疗开发领域.
背景情况:
- 该研究解决了在特定医疗条件下改善治疗选择的需求.
- 现有疗法可能在疗效或副作用方面存在局限性.
研究的目的:
- 评估试验药物的安全性和有效性.
- 为了确定目标患者群体的最佳剂量和治疗方案.
主要方法:
- 进行了一项随机,双盲,安慰剂控制的试验.
- 参与者在定义的治疗期内接受了研究药物或安慰剂.
- 通过临床评估和实验室测试来评估有效性和安全性终点.
主要成果:
- 初步结果表明,治疗组的关键疗效标记在统计学上显著改善.
- 副作用一般为轻度至中度,可控.
- 没有发现任何意外的安全问题.
结论:
- 试验药物在受试者群体中表现出良好的安全性和有效性.
- 需要进一步的研究来证实这些发现,并探索长期的结果.
关键词:
第二阶段第二阶段雷扎塔被采用了在 TP53 Y220C 中.癌症 癌症 癌症 癌症 癌症临床试验临床试验临床试验临床试验临床试验在 p53 里,p53 是一个 p53 的类型.再激活器的反应器固体瘤是一种固体瘤.更多相关视频
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
7.8K
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
9.2K
相关概念视频
02:57Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
02:56Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K